YIDU TECH (02158) spends 2 million Hong Kong dollars to repurchase outstanding shares, highlighting impressive mid-term performance for the 2026 fiscal year.

YIDU TECH (02158) announced that on December 3, the company repurchased 392,000 shares at a price of HK$5.09 per share, with a total repurchase amount of approximately HK$2 million. In recent news, YIDU TECH released its mid-year performance for the 2026 fiscal year and held an earnings conference. The report shows that during the reporting period, YIDU TECH's business maintained healthy growth, with total revenue reaching RMB 358 million, an increase of 8.7% year-on-year. The company's profit quality and operational efficiency have made significant progress: the adjusted EBITDA for existing business is about RMB 54 million, doubling compared to the same period last year, and the financial statements are close to breakeven. The achievement of this key financial milestone is about one year ahead of the company management's previous expectations. On the capital market front, securities firms continue to send positive signals. EB SECURITIES pointed out in a tracking research report that YIDU TECH continues to break through in the AI medical innovation field, with its medical large-scale model preliminarily constructing a "data + algorithm + scenario" flywheel closed loop, accelerating the technology's application in multiple scenarios. Citigroup also issued a report maintaining a "buy" rating for the company with a target price of HK$10, fully recognizing its core competitiveness and growth potential in the AI medical field.